Cibus, Inc. (NASDAQ:CBUS) Sees Large Growth in Short Interest

Cibus, Inc. (NASDAQ:CBUS) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 878,800 shares, a growth of 33.3% from the May 31st total of 659,100 shares. Based on an average trading volume of 111,500 shares, the short-interest ratio is presently 7.9 days. Approximately 5.8% of the shares of the company are sold short.

Cibus Stock Down 5.9 %

NASDAQ:CBUS traded down $0.58 during mid-day trading on Monday, hitting $9.27. 246,410 shares of the company traded hands, compared to its average volume of 100,506. The stock’s fifty day moving average price is $13.90 and its 200-day moving average price is $16.78. Cibus has a one year low of $8.31 and a one year high of $24.61. The firm has a market cap of $199.72 million, a price-to-earnings ratio of -0.51 and a beta of 1.92.

Cibus (NASDAQ:CBUS) last released its quarterly earnings data on Thursday, May 9th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.11). The business had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.40 million. Cibus had a negative return on equity of 23.33% and a negative net margin of 12,313.28%. During the same period last year, the company earned ($5.45) EPS. Equities analysts predict that Cibus will post -3.22 EPS for the current year.

Hedge Funds Weigh In On Cibus

A number of hedge funds have recently made changes to their positions in CBUS. Gladius Capital Management LP purchased a new stake in shares of Cibus in the fourth quarter worth about $56,000. Citigroup Inc. purchased a new stake in shares of Cibus in the third quarter worth about $199,000. Cerity Partners LLC purchased a new stake in shares of Cibus in the fourth quarter worth about $323,000. FineMark National Bank & Trust purchased a new stake in shares of Cibus in the third quarter worth about $300,000. Finally, Blue Trust Inc. purchased a new stake in shares of Cibus in the fourth quarter worth about $301,000. Institutional investors own 33.81% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Cibus in a report on Friday, May 10th.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.